Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Down 38.8% in December

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 93,300 shares, a decrease of 38.8% from the December 15th total of 152,400 shares. Based on an average daily volume of 111,600 shares, the short-interest ratio is currently 0.8 days. Approximately 2.1% of the company’s stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned about 11.30% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 8th.

Brainstorm Cell Therapeutics Price Performance

Shares of BCLI traded down $0.01 during mid-day trading on Tuesday, reaching $2.01. 17,671 shares of the company’s stock were exchanged, compared to its average volume of 53,633. The business’s fifty day simple moving average is $1.75 and its 200-day simple moving average is $3.23. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89. The stock has a market capitalization of $11.46 million, a PE ratio of -0.42 and a beta of 0.29.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.